一分钟看懂
这是一项关于Adenocarcinoma的II 期研究，登记的药物或干预包括TriAdeno vaccine；N-803，当前状态为尚未开始招募。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TriAdeno vaccine；N-803 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- * Histologically confirmed diagnosis of organ confined, low- or intermediate-risk PCa (Gleason grade group 1 or 2) identified in at least one prostate biopsy core. Biopsies performed at outside institutions should have Gleason score confirmed at the NCI by a g
- * Participants must be on active surveillance.
- * Pre-study treatment tissue availability (at least one formalin-fixed paraffin embedded \[FFPE\] biopsy core or one H and E-stained slide and at least 5 unstained slides) obtained between 3 and 24 months prior to treatment initiation is mandatory for study in
- * Serum PSA level of \<20 ng/mL (or \<10ng/mL for participants being treated with 5- alpha-reductase inhibitors)
- * Clinical stage \<=T2a by digital rectal exam (DRE)
- * Age \>=18 years
- * Eastern Cooperative Oncology Group (ECOG) performance status \<=1.
- * Adequate organ and marrow function as defined below:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07574541；登记信息更新于 2026-09-17。